Year: 2020

On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome in Q4 2020Reported positive ELEKTRA results; Ovid and Takeda plan to initiate phase 3 registrational program of OV935/TAK935 (soticlestat) in Dravet Syndrome and Lennox-Gastaut syndrome after upcoming end-of-phase 2 meeting with FDAReported encouraging trial results from ARCADE open-label Phase 2 trial of soticlestat and ENDYMION long-term extension trial showing seizure frequency reductions over time in CDKL5 deficiency disorder and Dup15q syndrome and global improvements beyond motor seizure reduction in both CDKL5 deficiency disorder and Dup15q syndrome patientsIn the ELEKTRA, ARCADE and ENDYMION trials, soticlestat appeared to be well-tolerated and demonstrated a safety profile consistent with the findings of previous studies with no...

COS COB, Conn., Nov. 12, 2020 (GLOBE NEWSWIRE) — Chicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE), one of the largest operators of streaming advertising-supported video-on-demand (AVOD) networks, today announced its financial results for the third quarter ended September 30, 2020.Third Quarter 2020 Financial SummaryGross revenue of $20.0 million, compared to $13.9 million in the second quarter of 2020, and $17.0 million in the year-ago period.Net loss of $13.0 million compared to a net loss of $10.0 million in the second quarter of 2020, and a net loss of $13.3 million in the year-ago period; $12.0 million net loss before preferred dividends, compared to $9.0 million net loss in the second quarter 2020, and $12.4 million net loss before preferred dividends in the year-ago period.Adjusted EBITDA of $4.2 million, compared...

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported third quarter 2020 financial results.“In our first quarter as a public company, I am proud of our team’s unwavering focus on bringing our medicines to patients,” said Sanjiv Patel, M.D., president and chief executive officer of Relay Therapeutics. “In July, we completed and closed our initial public offering. In September, we dosed the first patient with our second targeted medicine, RLY-4008, the only selective small molecule inhibitor of FGFR2 in clinical development. We look forward to providing updates across our pipeline in 2021.”Second Quarter Financial HighlightsCash and Cash Equivalents:...

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW) (“Beam” or “the Company”), the leading provider of innovative sustainable technology for electric vehicle (EV) charging, outdoor media and energy security, today announced financial results for the third fiscal quarter ended September 30, 2020.Third Quarter and Recent Company HighlightsInitiated Media business unit with the successful closing of an agreement with the City of San Diego, the Company’s first city contracted to host a sponsored network of EV ARC™ terminals. The Company believes this agreement will lead to the acquisition of our first sponsor and a significant recurring revenue business model which we believe we can replicate in other major cities.Prepared for planned growth through the addition of approximately $10.5 million cash to our balance...

Revenue growth reflects rebound of inpatient colonoscopy volumes in Q3 and increased demand for the Pure-Vu system from early adopter hospitalsQ3 Pure-Vu-enabled procedures increased by more than 50% above prior quarterly averageFirst major metropolitan health system collaboration intends to utilize Pure-Vu as new standard for facilitating inpatient colonoscopy.FORT LAUDERDALE, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate update.“In Q3 there...

Positive Response to Beta Testing of New Cybersecurity Solution andStrengthened Balance Sheet with Successful Follow-On OfferingPLANO, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) — INTRUSION, Inc. (NASDAQ: INTZ) announced today financial results for the three- and nine-month periods ended September 30, 2020.Third Quarter and Recent Business HighlightsWith positive beta-testing results, accepts pre-orders for INTRUSION Shield™$18.1 million in net proceeds raised from a public offering of common sharesSuccessfully uplisted to the Nasdaq Capital MarketExpansion of executive team with key appointments to support growth strategy“While extended government shutdowns associated with the pandemic continued to impact our legacy subscription and reporting businesses during the third quarter, the growing trend of sophisticated cybersecurity attacks...

BURLINGAME, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended September 30, 2020, and clinical development and operational highlights.“We are very pleased to report that during the third quarter we continued to make substantial progress in advancing our next generation anti-CD47 therapeutic, ALX148, in clinical trials in advanced gastric/gastroesophageal junction cancer and head and neck squamous cell cancers, as well as securing a clinical trial collaboration with Merck to study the combination of ALX148 with KEYTRUDA® in the setting of first line, metastatic or unresectable, recurrent head and neck squamous cell cancer,”...

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality (AR) for eCommerce, AR learning applications, and AR-enhanced video conferencing and virtual experiences, reported record results for its third quarter ended September 30, 2020. All figures are prepared in accordance with International Financial Reporting Standards (IFRS) unless otherwise indicated.Q3 2020 Financial highlights:Total Bookings $6.7 million +327% growth over Q3 2019Record revenue grows 200% to $4.7 millionRecord backlog of $2 millionGross Profit grows 344% to $3.0 million with a 63% marginWorking Capital of $13.6 millionFull report has been filed and is available on SEDAR Live Q3 earnings call will be after the close today at 4:30pmBridge Name: NexTech...